Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
Superluminal Medicines has raised $120.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Superluminal Medicines's investors include Insight Partners, Gaingels, NVIDIA, Eli Lilly, RA Capital Management.
Superluminal Medicines is headquartered in Boston, United States.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
Superluminal Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Superluminal Medicines — Funding & Investors." VCBacked, September 9, 2024, https://www.vcbacked.co/company/superluminal-medicines. Accessed September 13, 2026.
VCBacked. (2024). Superluminal Medicines — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/superluminal-medicines
{{cite web |title=Superluminal Medicines — Funding & Investors |url=https://www.vcbacked.co/company/superluminal-medicines |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated